{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:16:17Z","timestamp":1792145777230,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40256-026-00795-8","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:47:51Z","timestamp":1776833271000},"page":"559-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-5673","authenticated-orcid":false,"given":"Daniel","family":"Caldeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Av\u00f3-Bai\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Prada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"11","key":"795_CR1","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","volume":"57","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953\u201375. https:\/\/doi.org\/10.1194\/jlr.R071233.","journal-title":"J Lipid Res"},{"issue":"2","key":"795_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/SJ.EJHG.5201512","volume":"14","author":"K Schmidt","year":"2006","unstructured":"Schmidt K, Kraft HG, Parson W, Utermann G. Genetics of the Lp(a)\/apo(a) system in an autochthonous Black African population from the Gabon. Eur J Hum Genet. 2006;14(2):190\u2013201. https:\/\/doi.org\/10.1038\/SJ.EJHG.5201512.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"795_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/J.JACL.2019.04.010","volume":"13","author":"DP Wilson","year":"2019","unstructured":"Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374\u201392. https:\/\/doi.org\/10.1016\/J.JACL.2019.04.010.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"795_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/J.JACC.2017.11.014","volume":"71","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI working group recommendations to reduce Lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177\u201392. https:\/\/doi.org\/10.1016\/J.JACC.2017.11.014.","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"795_CR5","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/EURHEARTJ\/EHAC361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAC361.","journal-title":"Eur Heart J"},{"issue":"34","key":"795_CR6","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/EURHEARTJ\/EHAB484","volume":"42","author":"F Visseren","year":"2021","unstructured":"Visseren F, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB484.","journal-title":"Eur Heart J"},{"key":"795_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/S40618-022-02001-3","author":"D Caldeira","year":"2023","unstructured":"Caldeira D, Alves M, Ferreira JJ, Pinto FJ. Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort. J Endocrinol Investig. 2023. https:\/\/doi.org\/10.1007\/S40618-022-02001-3.","journal-title":"J Endocrinol Investig"},{"key":"795_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07093-8","author":"MM Antunes","year":"2020","unstructured":"Antunes MM, Alves M, Ferreira JJ, Pinto FJ, Caldeira D. Aspirin for primary cardiovascular prevention in patients with family history of cardiovascular disease: meta-analysis. Cardiovasc Drugs Ther. 2020. https:\/\/doi.org\/10.1007\/s10557-020-07093-8.","journal-title":"Cardiovasc Drugs Ther"},{"key":"795_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.N71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/BMJ.N71.","journal-title":"BMJ"},{"key":"795_CR10","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane, 2019.","DOI":"10.1002\/9781119536604"},{"key":"795_CR11","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. The risk of bias in non-randomized studies\u2014of interventions (ROBINS-I) assessment tool ROBINS-I tool (Stage I): at protocol stage. Published online 2016:1\u201322."},{"issue":"11","key":"795_CR12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1080\/14760584.2019.1690459","volume":"18","author":"D Caldeira","year":"2019","unstructured":"Caldeira D, Rodrigues B, David C, Costa J, Pinto FJ, Ferreira JJ. The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. Expert Rev Vaccines. 2019;18(11):1211\u20137. https:\/\/doi.org\/10.1080\/14760584.2019.1690459.","journal-title":"Expert Rev Vaccines"},{"key":"795_CR13","unstructured":"Sch\u00fcnemann H, Oxman A, Higgins J, et al. Chapter 11: PRESENTING results and \u2018summary of findings\u2019 tables. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration; 2011."},{"key":"795_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102068","author":"AC Razavi","year":"2025","unstructured":"Razavi AC, Chen J, Yang W, et al. Primary prevention aspirin, lipoprotein(a), and cardiorenal outcomes in chronic kidney disease: chronic renal insufficiency cohort. JACC Adv. 2025. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102068.","journal-title":"JACC Adv."},{"key":"795_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100674","author":"AC Razavi","year":"2024","unstructured":"Razavi AC, Richardson LTC, Coronado F, et al. Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a). Am J Prev Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100674.","journal-title":"Am J Prev Cardiol"},{"key":"795_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/EURJPC\/ZWAF547","author":"LD Colantonio","year":"2025","unstructured":"Colantonio LD, Wang Z, Ghazi L, et al. Aspirin use and the risk for cardiovascular disease by lipoprotein(a) levels: a multi-cohort study. Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAF547.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"795_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","volume":"203","author":"DI Chasman","year":"2009","unstructured":"Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203(2):371\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.07.019.","journal-title":"Atherosclerosis"},{"issue":"14","key":"795_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/J.JACC.2022.07.027","volume":"80","author":"P Lacaze","year":"2022","unstructured":"Lacaze P, Bakshi A, Riaz M, et al. Aspirin for primary prevention of cardiovascular events in relation to Lipoprotein(a) genotypes. J Am Coll Cardiol. 2022;80(14):1287. https:\/\/doi.org\/10.1016\/J.JACC.2022.07.027.","journal-title":"J Am Coll Cardiol"},{"key":"795_CR19","doi-asserted-by":"publisher","unstructured":"Ariyo A, Hennekens CH, Stampfer MJ, Ridker PM. Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the physician\u2019s health study. J Cardiovasc Risk. 1998;5(4):273\u20138. https:\/\/doi.org\/10.1177\/174182679800500410","DOI":"10.1177\/174182679800500410"},{"issue":"3","key":"795_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033562","volume":"13","author":"HS Bhatia","year":"2024","unstructured":"Bhatia HS, Trainor P, Carlisle S, et al. Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi\u2010ethnic study of atherosclerosis. J Am Heart Assoc. 2024;13(3):33562. https:\/\/doi.org\/10.1161\/JAHA.123.033562.","journal-title":"J Am Heart Assoc"},{"key":"795_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2019.11.004","author":"D Caldeira","year":"2020","unstructured":"Caldeira D, Alves M, David C, Costa J, Ferreira JJ, Pinto FJ. Aspirin in the primary prevention of cardiovascular disease on diabetic patients: systematic review and meta-analysis. Prim Care Diabetes. 2020. https:\/\/doi.org\/10.1016\/j.pcd.2019.11.004.","journal-title":"Prim Care Diabetes"},{"issue":"23","key":"795_CR22","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/J.JACC.2019.03.501","volume":"73","author":"HK Abdelaziz","year":"2019","unstructured":"Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for primary prevention of cardiovascular events. J Am Coll Cardiol. 2019;73(23):2915\u201329. https:\/\/doi.org\/10.1016\/J.JACC.2019.03.501.","journal-title":"J Am Coll Cardiol"},{"key":"795_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/J.ATHEROSCLEROSIS.2022.04.020","volume":"349","author":"GG Schwartz","year":"2022","unstructured":"Schwartz GG, Ballantyne CM. Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis. 2022;349:110\u201322. https:\/\/doi.org\/10.1016\/J.ATHEROSCLEROSIS.2022.04.020.","journal-title":"Atherosclerosis"},{"key":"795_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/EURJPC\/ZWAF589","volume":"00","author":"MD Shapiro","year":"2025","unstructured":"Shapiro MD, Ruscica M. Aspirin and Lipoprotein(a): lessons from replication at scale. Eur J Prev Cardiol. 2025;00:1\u20133. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAF589.","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"795_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(25)00877-0","volume":"85","author":"C Gurevitz","year":"2025","unstructured":"Gurevitz C, Zafar MU, Katragadda JK, et al. High LP(A) increases thrombogenicity particularly in patients with RS3798220-CSNP. J Am Coll Cardiol. 2025;85(12):393. https:\/\/doi.org\/10.1016\/S0735-1097(25)00877-0.","journal-title":"J Am Coll Cardiol"},{"key":"795_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHAF190","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAF190.","journal-title":"Eur Heart J"}],"updated-by":[{"DOI":"10.1007\/s40256-026-00805-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000}}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00795-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00795-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00795-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:45:45Z","timestamp":1787309145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00795-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00795-8","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct the sentence starting \"This article also reported data...\".","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40256-026-00805-9","URL":"https:\/\/doi.org\/10.1007\/s40256-026-00805-9","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.C., in the last 2 years, has participated in educational meetings and\/or attended a conferences or symposia (including travel, accommodation and\/or hospitality), and\/or received honoraria for consulting or lecturing from Daiichi Sankyo, Menarini, outside the scope of this work. F.J.P received honoraria for consulting or lecturing from Boehringer-Ingelheim, Bayer Healthcare, Novartis, Menarini, Servier, Daichi Sankyo, Vifor International, Pfizer outside the scope of this work. The other authors do not have any conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: D.C. ; methodology: D.C.; software management: R.A.B, A.L, L.P., D.C. ; validation: D.C., M.A., R.A.B, A.L, L.P. and F.J.P.; formal analysis: D.C.; Data retrieval and curation: R.A.B, A.L, L.P., D.C.; writing\u2014original draft preparation: D.C.; critical appraisal, writing\u2014review and editing with substantial contributions: D.C., M.A., R.A.B, A.L, L.P. and F.J.P.; all authors have read and agreed to the published version of the manuscript.","order":2,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data were pooled based on published meta-data.","order":3,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}